Updates on HERA study?

Save as Favorite
Sign in to receive recommendations (Learn more)
Question from KathyM: Are there any updates about the 2-year arm of the HERA study? I was in the 2-year study and am very interested, especially around relapse. Thank you.
Answers - Generosa Grana, M.D., F.A.C.P There is no data yet available on the HERA group that received 2 years of Herceptin (chemical name: trastuzumab). For the present, the standard remains 1 year of therapy. And we look forward to that data becoming available.

The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.

Editor's Note: This conference took place in June 2008.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.



Springappeal300x125 nm a
Back to Top